These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25707960)

  • 1. Clinical pharmacology of bispecific antibody constructs.
    Rathi C; Meibohm B
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S21-8. PubMed ID: 25707960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies.
    Stanimirovic D; Kemmerich K; Haqqani AS; Farrington GK
    Adv Pharmacol; 2014; 71():301-35. PubMed ID: 25307221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab for the treatment of B-cell lymphoma.
    Oak E; Bartlett NL
    Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catumaxomab: a bispecific trifunctional antibody.
    Sebastian M; Kuemmel A; Schmidt M; Schmittel A
    Drugs Today (Barc); 2009 Aug; 45(8):589-97. PubMed ID: 19927225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies for cancer therapy: A review.
    Krishnamurthy A; Jimeno A
    Pharmacol Ther; 2018 May; 185():122-134. PubMed ID: 29269044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics.
    Moore DC; Digiantonio N; Oxencis CJ; Taucher KD
    Am J Health Syst Pharm; 2024 Jul; 81(14):574-582. PubMed ID: 38394329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
    Yuraszeck T; Kasichayanula S; Benjamin JE
    Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
    Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
    Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.